Sign In
Buy BIAF
$1.69
+0.0100 (+0.595%)
At Close: Jun 03, 2026
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
08:00am, Friday, 14'th Nov 2025
SAN ANTONIO--(BUSINESS WIRE)-- #AI--bioAffinity Technologies reports Q3 2025 financial results, achieves 86% increase in CyPath® Lung testing revenue.
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
08:00am, Wednesday, 05'th Nov 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announced the volume of CyPath® Lung tests processed in October increased by 111% over the 2025 monthly average.
SAN ANTONIO--(BUSINESS WIRE)-- #AI--Australian Patent Office accepts bioAffinity Technologies' patent application for its platform technology to assess lung health and predict disease.
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
08:00am, Monday, 20'th Oct 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies will present research related to its noninvasive CyPath Lung test for lung cancer at CHEST 2025.
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #AI--The US Patent and Trademark Office will issue BIAF a new patent on its flow cytometry+AI platform that detects lung cancer as early as Stage 1A.
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
08:00am, Wednesday, 15'th Oct 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies received written notice from Nasdaq stating that the Company has regained compliance with continued listing requirements.
JERSEY CITY, N.J. , Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed on a $1.8 million registered direct offering of common stock.
JERSEY CITY, N.J. , Oct. 8, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces a $1.8 million registered direct offering of common stock.
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
08:00am, Tuesday, 07'th Oct 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the previous quarter.
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
12:44pm, Tuesday, 30'th Sep 2025
JERSEY CITY, N.J. , Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies,
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
12:15pm, Tuesday, 30'th Sep 2025
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes $4.8 million public offering.
WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m
05:59pm, Monday, 29'th Sep 2025
JERSEY CITY, N.J. , Sept. 29, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, I
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
03:51pm, Monday, 29'th Sep 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $4.8 million public offering.
